Ventripoint Unveils Whitepaper on Advanced AI-Powered Heart Imaging Software
Toronto, Ontario -- March 24, 2025 -- NewsGenie -- Ventripoint Diagnostics Ltd. (TSXV:VPT; OTC:VPTDF) has released a whitepaper comparing its VMS+ 4.0 advanced Automated Radiological Image Processing Software/System to the previous VMS+ 3.0 model.
The VMS+ 4.0, recently cleared by the U.S. FDA via 510(k), includes several enhancements:
- AI-assisted automated point placement
- User tools for cardiac view analysis
- Enhanced visualization tools
- Measurements from 3D wire mesh (ED Volume, ED Volume Index, ES Volume, ES Volume Index, Ejection Fraction, Cardiac Output, Cardiac Index, Stroke Volume, Stroke Volume Index)
- Reporting of all measurements and derived parameters
VMS+ connects to standard echocardiography machines and uses AI to select anatomical landmarks from echocardiogram images, which are then used with Ventripoint’s Knowledge Based Reconstruction AI technology to create 3D visualizations of the heart. This calculates volumes and ejection fraction for all 4 cardiac chambers with accuracy equivalent to MRI. The combination of AI engines improves analysis reliability.
Ventripoint President and CEO, Hugh MacNaught, stated that the company has invested in R&D to enhance ease-of-use and clinical workflow integration. He added that VMS+ 4.0 was developed with clinical collaborators to assess the performance of automated features. The whitepaper illustrates the robustness and performance of VMS+, offering hospitals an efficient, non-invasive heart-imaging tool.
VMS+ 4.0 has received regulatory clearance in the U.S., E.U., U.K., and Canada.
The whitepaper is available at www.ventripoint.com.
Ventripoint is an industry leader in AI for echocardiography. Its VMS+ products use Knowledge Based Reconstruction technology, providing volumetric cardiac measurements equivalent to MRI. The VMS+ can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe, and Canada.